D. T. Lau

Publications38
h-index19
Citations1,651
Highly Influential Citations74
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • P. Marcellin
  • 1,002 Publications, 57,043 Citations
  • F. Zoulim
  • 810 Publications, 30,360 Citations
  • J. Hoofnagle
  • 541 Publications, 55,944 Citations
  • S. Hadziyannis
  • 286 Publications, 18,922 Citations
  • Publications
  • Influence
Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection.
  • Y. Loo, D. Owen, +15 authors M. Gale
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences…
  • 11 April 2006
Viral signaling through retinoic acid-inducible gene-I (RIG-I) and its adaptor protein, IFN promoter-stimulator 1 (IPS-1), activates IFN regulatory factor-3 (IRF-3) and the host IFN-alpha/beta… Expand
  • 400
  • 31
  • PDF
Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector
Interferon (IFN) α inhibits hepatitis C virus (HCV) replication both clinically and in vitro; however, the complete spectrum of interferon‐stimulated genes (ISGs) expressed in the HCV‐infected liver… Expand
  • 225
  • 10
Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection.
BACKGROUND & AIMS In patients with hepatitis C virus (HCV) infection, interferon alfa (IFN-α) alters expression of IFN-stimulated genes (ISGs), but little is understood about factors that determine… Expand
  • 68
  • 6
APRI: An Easy and Validated Predictor of Hepatic Fibrosis in Chronic Hepatitis C
Goals To evaluate the aspartate aminotransferase/platelet ratio index (APRI) as a predictor of the presence or absence of significant fibrosis on liver biopsy of patients with chronic hepatitis C… Expand
  • 120
  • 5
IFITM1 is a tight junction protein that inhibits hepatitis C virus entry†, ‡
Type 1 interferon (IFN) continues to be the foundation for the current standard of care combination therapy for chronic hepatitis C virus (HCV) infection, yet the component interferon‐stimulated… Expand
  • 121
  • 4
Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype.
BACKGROUND & AIMS Chronic hepatitis B virus (HBV) infection is an important cause of cirrhosis and hepatocellular carcinoma worldwide; populations that migrate to the United States and Canada might… Expand
  • 52
  • 4
Intrahepatic gene expression profiles and alpha‐smooth muscle actin patterns in hepatitis C virus induced fibrosis
To gain insight into pathogenic mechanisms underlying fibrosis in hepatitis C virus (HCV)‐mediated liver injury, we compared intrahepatic gene expression profiles in HCV‐infected patients at… Expand
  • 62
  • 2
A Framework for Management of Hepatitis C in Prisons
Inmates with chronic hepatitis C virus (HCV) infection present a major challenge to prison health systems. In the United States, prisons house approximately 1.4 million adults serving sentences that… Expand
  • 102
  • 2
A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update.
Chronic hepatitis B (CHB) continues to be an important public health problem worldwide, including in the United States. An algorithm for managing CHB was developed by a panel of United States… Expand
  • 79
  • 2
  • PDF
A Pilot Study of Extended Duration Peginterferon Alfa-2a for Patients With Hepatitis B e Antigen-Negative Chronic Hepatitis B
OBJECTIVES:Forty-eight weeks of peginterferon alfa-2a is the approved regimen for chronic hepatitis B (CHB). Standard interferon is more effective for hepatitis B e antigen (HBeAg)-negative CHB when… Expand
  • 55
  • 2